Table 1.
Patients characteristics and outcomes according to weight (n = 92) and skeletal muscle loss (n = 101) set analysis
| Characteristics | Skeletal muscle loss (n = 101), n (%) | Weight loss (n = 92), n (%) | |
|---|---|---|---|
| Gender (male) | 71 (70.3) | 65 (70.7) | |
| Prior nephrectomy | 84 (83.2) | 80 (87.0) | |
| Weight (kg), mean [min–max] | 74.0 [43.0–120.0] | 74.1 [48.0–120.0] | |
| Age (years), mean [min–max] | 59.2 [22.0–78.0] | 60.4 [28.0–78.0] | |
| BMI (kg/cm2), mean [min–max] | 25.0 [16.4–49.3] | 25.0 [16.6–49.3] | |
| BMI | <20 | 13 (13.1) | 10 (10.9) |
| [20–25] | 43 (43.4) | 41 (44.6) | |
| [25–30] | 34 (34.3) | 34 (37.0) | |
| ≥30 | 9 (9.1) | 7 (7.6) | |
| Missing, n | 2 | 0 | |
| Histology | Clear cell RCC | 75 (74.3) | 72 (78.3) |
| Non‐clear cell RCC | 26 (25.7) | 20 (21.7) | |
| Performance status | 0–1 | 73 (72.2) | 68 (74.0) |
| ≥2 | 28 (27.7) | 24 (26.1) | |
| IMDC score at baseline | |||
| Good | 13 (13.0) | 13 (14.3) | |
| Intermediate | 63 (63.0) | 57 (62.6) | |
| Poor | 24 (24.0) | 21 (23.1) | |
| Missing, n | 1 | 1 | |
| Previous systemic treatment | |||
| 0 | 3 (3.0) | 3 (3.3) | |
| 1 | 31 (30.7) | 27 (29.4) | |
| 2 | 27 (26.7) | 26 (28.3) | |
| ≥3 | 40 (39.6) | 36 (39.1) | |
| Duration of exposure under cabozantinib (months), mean [min–max] | 12.1 [1.0–32.1] | 12.3 [1.0–32.1] | |
| Sarcopenia at baseline | |||
| Yes | 30 (29.7) | — | |
| No | 71 (70.3) | — | |
| Outcomes | |||
| Disease control rate at 3 months | 94 (93.1) | 86 (93.5) | |
| Objective response rate | 37 (36.6) | 35 (38.0) | |
| Progression‐free survival (months), mean [min–max] | 9.2 [7.6–10.6] | 8.9 [7.4–10.1] | |
| Overall survival (months), mean [min–max] | 19.8 [17.7–23.7] | 20.1 [17.7–29.7] | |
| Overall Grades 3–4 toxicities (CTCAEv4) | 35 (34.7) | 33 (35.9) | |
BMI, body mass index; IMDC, International Metastatic RCC Database Consortium; SMA, skeletal muscle loss analysis.